FINANCINGS

Amag Pharmaceuticals Inc. priced $175 million worth of 2.5 percent convertible senior notes due in 2019.

Argos Therapeutics Inc. raised $45 million from its initial public offering (IPO).

Auspex Pharmaceuticals Inc. completed its IPO of 8.05 million shares of common stock at $12 each.

Bioblast Pharma Ltd. is seeking to raise $37.5 million from an IPO.

Biodelivery Sciences International Inc. sold $60 million worth of shares in a registered direct offering.

Clarus Ventures LLC disclosed in an SEC filing that it plans to raise a $375 million fund.

Concert Pharmaceuticals Inc. priced its IPO and raised $84 million.

Egalet Corp. closed its IPO of 4.2 million shares at $12 per share.

Eleven Biotherapeutics inc. closed its IPO of 5.75 million shares of common stock at $10 per share.

Five Prime Therapeutics Inc. closed a public offering generating gross proceeds of $43.1 million.

Flexion Therapeutics Inc. priced its IPO of 5 million shares of common stock at $13 each.

Genocea Biosciences Inc. closed its IPO of 5.5 million shares at $12 each.

Halozyme Therapeutics Inc. closed its public offering for net proceeds of approximately $107.8 million.

Idera Pharmaceuticals Inc. closed its public offering for gross proceeds of approximately $40 million.

Ironwood Pharmaceuticals Inc. closed a public offering for net proceeds of approximately $190.4 million.

Macrogenics Inc. priced a public offering selling 1.8 million of the shares for $65.7 million.

Melinta Therapeutics Inc. raised $70 million to support its delafloxacin new drug application.

Nephrogenex Inc. priced its IPO of 3.1 million shares at $12 apiece for a raise of $37.2 million.

PDL BioPharma Inc. closed its offering of $300 million in convertible senior unsecured notes.

Plandai Biotechnology Inc. said Lincoln Park Capital Fund LLC has committed to invest up to $15.3 million.

PTC Therapeutics Inc. priced a public offering for $109.7 million, selling 4.4 million shares at $24.50 each.

Puma Biotechnology Inc. raised $138 million from a public offering of shares at $122.50 each.

UniQure B.V. closed its initial public offering of 5.4 million ordinary shares at $17 each.

Voyager Therapeutics Inc. raised $45 million in a Series A financing round.

DEALS

Agenus Inc. completed its acquisition of 4-Antibody AG.

Apricus Biosciences Inc. signed an agreement with Recordati SpA to market Vitaros (alprostadil).

Mallinckrodt plc is acquiring Cadence Pharmaceuticals Inc. for approximately $1.3 billion.

Mast Therapeutics Inc. has agreed to acquire Aires Pharmaceuticals Inc.

Merck & Co. Inc. and Samsung Bioepis Co. Ltd. have expanded their collaboration.

Retrophin Inc. signed an agreement to acquire Manchester Pharmaceuticals LLC for $62.5 million.

. . . AND MORE

Alcobra Ltd. submitted an investigational new drug application to start a phase III trial with MG01CI in adults with attention deficit disorder.

Celgene Corp. said the board of directors voted to recommend a 2-for-1 stock split.

Sigma-Tau Pharmaceuticals Inc. is developing a live organism used to repopulate patients’ gastrointestinal tracks.

The Cardiovascular and Renal Drugs Advisory Committee voted against approving The Medicines Co.’s cangrelor antiplatelet drug.